Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238479 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 490
- Enrollment target
- 20
- Study locations
NCT06238479: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by Eli Lilly and Company.
NCT06238479 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 490 participants, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06238479, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 490 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Primary Outcome
Number of participants with dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG LY4101174
Study Locations (20)
Other
- Austin Health - Heidelberg
- Icon Cancer Centre Kurralta Park - Kurralta Park
- Institut Jules Bordet - Anderlecht
- Peking University First Hospital - Beijing
- Hunan Cancer Hospital - Changsha
- Shanghai East Hospital - Shanghai
- Centre Oscar Lambret - Lille
- Centre Leon Berard - Lyon
- Institut Paoli-Calmettes - Marseille
- CHU Strasbourg-Hautepierre - Strasbourg
- Gustave Roussy - Villejuif
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island - Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- UT Southwestern Medical Center - Dallas
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Florida
- AdventHealth Orlando - Orlando
Georgia
- Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2024-03-05 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT06238479 shows while recruiting
NCT06238479 is an interventional study that assigns participants to a tested intervention. The registered 490 participants enrollment target is mid-sized for trials with a published cap, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (25% lower).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which LY4101174 is the first listed.
NCT06238479 names 20 study sites across 7 states, led by Other, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06238479 about?
NCT06238479 is a clinical study titled "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors". The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study w...
What is the current status of trial NCT06238479?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 490 participants. The study started on 2024-03-05. Estimated completion is 2027-03.
What conditions does trial NCT06238479 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Advanced Solid Tumor, Cervical Cancer.
What interventions are being tested in trial NCT06238479?
The interventions under investigation include: LY4101174 (DRUG).
Who is sponsoring clinical trial NCT06238479?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238479 being conducted?
This trial has 20 study locations across Florida, Georgia, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06238479's enrollment target sits among peer trials
490 81st of 454 higher than 374 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- NCT06875622 · 490 participants · NA
Remote Approaches for Optimizing Weight Loss (Elevate Weight Loss Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI